<DOC>
	<DOCNO>NCT00304551</DOCNO>
	<brief_summary>This study evaluate clinical response efficacy safety combination therapy peginterferon alfa-2a ribavirin , compare antiviral treatment-free group CHC patient compensate LC . Additionally , study evaluate dosage reactivity pharmacokinetic characteristic combination therapy peginterferon alfa-2a ribavirin CHC patient compensate LC .</brief_summary>
	<brief_title>A Study Peginterferon Alfa-2a Combination With Ribavirin Chronic Hepatitis C ( CHC ) Patients With Compensated Liver Cirrhosis ( LC )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients age 20 75 yearsold quantifiable serum HCVRNA ( ≥ 500 IU/mL ) , elevate serum alanine aminotransferase activity ( ≥ 45 IU per liter ) within sixty day screen , proven CHC compensate LC ( ChildPugh A ) liver biopsy . Patients neutropenia ( few 1,500 neutrophil per cubic millimeter ) Thrombocytopenia ( few 75,000 platelet per cubic millimeter ) Anemia ( less 12 g hemoglobin per deciliter ) Hepatitis B coinfection ; decompensated liver disease . Organ transplant Creatinine clearance le 50 milliliter per minute Poorly control psychiatric disease Poorly control diabetes Malignant neoplastic disease Severe cardiac chronic pulmonary disease Immunologically mediate disease Retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>CHC compensate LC</keyword>
</DOC>